| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5360800 | SEBELA IRELAND LTD | Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives |
Jan, 2013
(11 years ago) | |
| US6284770 | SEBELA IRELAND LTD | Medicaments for the treatment of non-constipated female irritable bowel syndrome |
Oct, 2018
(5 years ago) | |
Lotronex is owned by Sebela Ireland Ltd.
Lotronex contains Alosetron Hydrochloride.
Lotronex has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Lotronex are:
- US5360800
- US6284770
Lotronex was authorised for market use on 23 December, 2003.
Lotronex is available in tablet;oral dosage forms.
Lotronex can be used as for women with severe diarrhea-predominant irritable bowel syndrome (ibs).
The generics of Lotronex are possible to be released after 05 October, 2018.
Drugs and Companies using ALOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 23 December, 2003
Treatment: For women with severe diarrhea-predominant irritable bowel syndrome (ibs)
Dosage: TABLET;ORAL
How can I launch a generic of LOTRONEX before it's drug patent expiration?
More Information on Dosage
LOTRONEX family patents
